Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer

Table 3 Univariate analysis of the correlation of clinicopathological parameters with overall survival in patients with colorectal carcinoma

	HR	95%CI	P value
Sex, male vs female	0.750	0.399-1.411	0.37
Age in yr, ≤ 60 vs > 60	0.899	0.472-1.714	0.74
Cancer, colon vs rectum	1.279	0.712-2.296	0.41
BMI, > 25 vs ≤ 25	1.579	0.697-3.579	0.21
Tumor differentiation, moderate and poor vs well	2.798	1.373-5.702	0.039
Stage, 3 vs 2	1.003	0.534-1.882	0.99
T stage, T4 vs T2/3	1.418	0.755-2.664	0.27
N stage, N1/2 vs N0	1.005	0.536-1.887	0.99
CEA in ng/mL, > 5 vs ≤ 5	2.137	1.141-4.004	0.025
CA19-9 in U/mL, > 37 vs ≤ 37	1.262	0.547-2.911	0.56
CD3 TILs, high vs low	1.195	0.649-2.198	0.55
CD8 TILs, high vs low	2.096	0.975-4.504	0.018
Nuclear IDO1, high vs low	2.044	0.871-4.798	0.039
Cytoplasmic IDO1, high vs low	1.690	0.901-3.173	0.10
Nuclear and cytoplasmic IDO1, high vs low	2.044	0.871-4.798	0.039
COX2, high vs low	1.235	0.659-2.314	0.51
Nuclear IDO1/COX2, IV vs I/II/III	3.048	0.868-10.7	0.0049
Cytoplasmic IDO1/COX2, IV vs I/II/III	2.109	0.976-4.558	0.022
Treatment group, celecoxib vs non-celecoxib	0.943	0.489-1.826	0.86

BMI: Body mass index; CA: Cancer antigen; CEA: Carcinoembryonic antigen; CI: Confidence interval; COX2: Cyclooxygenase 2; CRC: Colorectal carcinoma; HR: Hazard ratio; IDO1: Indoleamine-2,3-dioxygenase 1; TILs: Tumor infiltrating lymphocytes.